Total Payments
$127,236
2024 Payments
$24,376
Companies
19
Transactions
154
Medicare Patients
240
Medicare Billing
$18,209
Payment Breakdown by Category
Consulting$94,755 (74.5%)
Travel$18,276 (14.4%)
Other$6,315 (5.0%)
Research$4,000 (3.1%)
Food & Beverage$3,717 (2.9%)
Education$173.35 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $94,755 | 44 | 74.5% |
| Travel and Lodging | $18,276 | 47 | 14.4% |
| Unspecified | $4,000 | 2 | 3.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,825 | 3 | 3.0% |
| Food and Beverage | $3,717 | 54 | 2.9% |
| Honoraria | $2,490 | 1 | 2.0% |
| Education | $173.35 | 3 | 0.1% |
Payments by Type
General
$123,236
152 transactions
Research
$4,000
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Retrophin, Inc. | $44,540 | 50 | $0 (2019) |
| Alnylam Pharmaceuticals Inc. | $21,686 | 25 | $0 (2024) |
| Novo Nordisk Inc | $15,882 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $13,646 | 23 | $0 (2020) |
| Novo Nordisk AS | $11,549 | 8 | $0 (2024) |
| Travere Therapeutics, Inc. | $4,371 | 4 | $0 (2024) |
| SANOFI US SERVICES INC. | $2,855 | 1 | $0 (2023) |
| Novo Nordisk Health Care AG | $2,700 | 1 | $0 (2023) |
| Horizon Therapeutics plc | $2,629 | 2 | $0 (2021) |
| Sumitomo Dainippon Pharma Co., Ltd. | $2,625 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,376 | 30 | Alnylam Pharmaceuticals Inc. ($9,372) |
| 2023 | $19,038 | 19 | Novo Nordisk Inc ($6,332) |
| 2022 | $9,297 | 10 | Alnylam Pharmaceuticals Inc. ($4,951) |
| 2021 | $11,698 | 12 | Novo Nordisk AS ($4,000) |
| 2020 | $4,009 | 3 | AstraZeneca Pharmaceuticals LP ($2,009) |
| 2019 | $15,725 | 33 | AstraZeneca Pharmaceuticals LP ($11,637) |
| 2018 | $13,824 | 15 | Retrophin, Inc. ($13,824) |
| 2017 | $29,269 | 32 | Retrophin, Inc. ($26,628) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/10/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $201.12 | General |
| Category: Genetic Disease | ||||||
| 11/10/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: Genetic Disease | ||||||
| 11/09/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $181.17 | General |
| Category: Genetic Disease | ||||||
| 11/09/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | In-kind items and services | $48.24 | General |
| Category: Genetic Disease | ||||||
| 11/09/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $7,960.60 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $174.95 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $145.75 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $145.75 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $145.75 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $145.75 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | In-kind items and services | $64.78 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | In-kind items and services | $10.80 | General |
| Category: Genetic Disease | ||||||
| 11/07/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $80.94 | General |
| Category: Genetic Disease | ||||||
| 10/26/2024 | Novo Nordisk Inc | Rivfloza (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Rare Disease | ||||||
| 10/24/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $5,287.50 | General |
| 10/24/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $740.00 | General |
| 10/24/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $626.71 | General |
| 10/24/2024 | Novo Nordisk AS | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $575.00 | General |
| 10/24/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $195.66 | General |
| 10/24/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $124.53 | General |
| 10/15/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| 04/11/2024 | Novo Nordisk Inc | Rivfloza (Drug) | Food and Beverage | In-kind items and services | $121.78 | General |
| Category: Rare Disease | ||||||
| 01/23/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $3,712.50 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 69 | 73 | $25,545 | $5,005 |
| 2022 | 3 | 63 | 66 | $26,560 | $5,403 |
| 2021 | 3 | 56 | 58 | $21,105 | $3,721 |
| 2020 | 2 | 52 | 55 | $23,600 | $4,080 |
Total Patients
240
Total Services
252
Medicare Billing
$18,209
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 27 | $14,850 | $2,882 | 19.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 27 | $10,125 | $2,065 | 20.4% |
| 81002 | Urinalysis, manual test | Office | 2023 | 18 | 19 | $570.00 | $58.76 | 10.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 34 | $18,700 | $3,804 | 20.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 20 | $7,500 | $1,557 | 20.8% |
| 81002 | Urinalysis, manual test | Office | 2022 | 12 | 12 | $360.00 | $41.18 | 11.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 27 | 29 | $10,875 | $1,925 | 17.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 18 | $9,900 | $1,757 | 17.8% |
| 81002 | Urinalysis, manual test | Office | 2021 | 11 | 11 | $330.00 | $38.28 | 11.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 36 | 38 | $14,250 | $2,338 | 16.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 17 | $9,350 | $1,742 | 18.6% |
About Dr. David Goldfarb, M.D
Dr. David Goldfarb, M.D is a Nephrology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629018908.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Goldfarb, M.D has received a total of $127,236 in payments from pharmaceutical and medical device companies, with $24,376 received in 2024. These payments were reported across 154 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($94,755).
As a Medicare-enrolled provider, Goldfarb has provided services to 240 Medicare beneficiaries, totaling 252 services with total Medicare billing of $18,209. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location New York, NY
- Active Since 06/07/2006
- Last Updated 04/01/2021
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629018908
Products in Payments
- (815) Thiola (Drug) $46,540
- OXLUMO (Drug) $17,336
- LOKELMA (Drug) $13,646
- KRYSTEXXA (Biological) $2,629
- Not Product Related (Medical Supply) $2,206
- Veltassa (Drug) $150.93
- Rivfloza (Drug) $139.86
- LITHOVUE (Device) $128.93
- Rayaldee (Drug) $125.00
- NephroCheck Test (Device) $124.85
- Thiola (Drug) $31.24
- Cook Medical Urology SIS (Device) $16.73
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in New York
Dr. Gerald Appel, M.d, M.D
Nephrology — Payments: $842,842
Nephrology $842,842
Dr. Richard Chan, Md, MD
Nephrology — Payments: $525,489
Nephrology $525,489
Dr. Steven Coca, D.o., M.s, D.O., M.S
Nephrology — Payments: $388,012
Nephrology $388,012
Dr. Jai Radhakrishnan, M.d, M.D
Nephrology — Payments: $243,935
Nephrology $243,935
Dr. David Bernard, Md, MD
Nephrology — Payments: $235,726
Nephrology $235,726
Dr. Girish Nadkarni, Md, MD
Nephrology — Payments: $217,113
Nephrology $217,113